MAPT and Alzheimer disease: Specifically, acetylation at Lys174 has been recently identified in AD brains and it seems that it may contribute to retard tau turnover being critical for tau-induced toxicity, which has opened new therapeutic perspectives for the treatment of AD and other human tauopathies [38].